Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance.

Molecular Cancer Therapeutics
Margaret L DahnPaola Marcato

Abstract

Dysregulation of DNA methylation is an established feature of breast cancers. DNA demethylating therapies like decitabine are proposed for the treatment of triple-negative breast cancers (TNBC) and indicators of response need to be identified. For this purpose, we characterized the effects of decitabine in a panel of 10 breast cancer cell lines and observed a range of sensitivity to decitabine that was not subtype specific. Knockdown of potential key effectors demonstrated the requirement of deoxycytidine kinase (DCK) for decitabine response in breast cancer cells. In treatment-naïve breast tumors, DCK was higher in TNBCs, and DCK levels were sustained or increased post chemotherapy treatment. This suggests that limited DCK levels will not be a barrier to response in patients with TNBC treated with decitabine as a second-line treatment or in a clinical trial. Methylome analysis revealed that genome-wide, region-specific, tumor suppressor gene-specific methylation, and decitabine-induced demethylation did not predict response to decitabine. Gene set enrichment analysis of transcriptome data demonstrated that decitabine induced genes within apoptosis, cell cycle, stress, and immune pathways. Induced genes included those character...Continue Reading

References

Apr 6, 2000·Journal of the National Cancer Institute·M EstellerJ G Herman
Dec 19, 2001·The Journal of Pathology·Manel Esteller, James G Herman
Jul 15, 2005·Seminars in Hematology·Richard L Momparler
Oct 20, 2005·Journal of the National Cancer Institute·Frank Lyko, Robert Brown
Mar 14, 2007·Cancer Cell·Michail ShipitsinKornelia Polyak
Sep 16, 2009·Carcinogenesis·Shikhar SharmaPeter A Jones
Dec 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lanlan ShenJean-Pierre J Issa
Aug 23, 2011·PloS One·Taichun QinJean-Pierre J Issa
Feb 2, 2012·International Journal of Breast Cancer·Parvin F PeddiCynthia Ma
Feb 24, 2012·Nucleosides, Nucleotides & Nucleic Acids·Vijaya L DamarajuZeen Tong
Jul 28, 2012·Journal of Mammary Gland Biology and Neoplasia·Roisin Connolly, Vered Stearns
Apr 4, 2013·Science Signaling·Jianjiong GaoNikolaus Schultz
Oct 25, 2013·Nature·Rahul M Kohli, Yi Zhang
Jan 3, 2014·The Journal of Clinical Investigation·Marianne B TreppendahlKirsten Grønbæk
Feb 26, 2015·Frontiers in Pharmacology·Marçal Pastor-Anglada, Sandra Pérez-Torras
May 29, 2015·European Journal of Haematology·Maria Teresa VosoUNKNOWN GROM (Gruppo Romano e Laziale MDS) and Basilicata MDS Registry
Sep 14, 2016·The Journal of Investigative Dermatology·Valeria LucariniFabrizio Mattei
Sep 15, 2017·The Journal of Pharmacology and Experimental Therapeutics·Steven R HallKerry B Goralski
Dec 6, 2017·Proceedings of the National Academy of Sciences of the United States of America·Meredith L StoneCynthia A Zahnow
Dec 14, 2018·Blood·Valeria Santini

❮ Previous
Next ❯

Citations

Jul 22, 2020·World Journal of Surgical Oncology·Danjun SongXiaoying Wang
Mar 7, 2021·Journal of Clinical Medicine·Sarah D MüllerTobias Piegeler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.